EGF and schizophrenia: Epidermal growth factor receptor (ErbB) and epidermal growth factor (EGF) as the ligand of ErbB have been found to be involved in the development of both gliomas and schizophrenia (Berezowska and Schlegel, 2011; Sotoyama et al., 2011; Iwakura and Nawa, 2013; Brocard et al., 2015); thus, psychiatric drugs targeting the EGF/ErbB signaling pathway can also be expected to affect gliomas in patients with schizophrenia.